# Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion.

> **NCT07361224** · PHASE1 · RECRUITING · sponsor: **Tel-Aviv Sourasky Medical Center** · enrollment: 12 (estimated)

## Conditions studied

- Large B-Cell Lymphoma (LBCL)

## Interventions

- **DRUG:** rhDNase I

## Key facts

- **NCT ID:** NCT07361224
- **Lead sponsor:** Tel-Aviv Sourasky Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2027-02
- **Final completion:** 2028-02
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07361224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07361224, "Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion.". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT07361224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*